Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation
Detection Principle
ImmunoAssay-Antibody
Target
IgG, IgA, IgM
Testing Method Category
Testing Method
Multiple-kits
Testing Method - Additional Info
Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison SARS-CoV-2 S1/S2 IgG (research use only), Euroimmun SARS-CoV-2 IgG and IgA (CE marked), 2 rapid lateral flow (immunocromatographic) tests :Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-CoV-2 IgG/IgM (CE marked) in comparison with a microneutralisation test (MNT)
Reported Performance
Specificity, Sensitivity: 95.1%, 80.5% (Abbott Architect SARS-CoV-2 IgG); 94.9%, 43.8% (Diasorin Liaison SARS-CoV-2 IgG); 68.3%, 87.8% (Euroimmun SARS-CoV-2 IgA), 86.6%, 70.7% (Euroimmun SARS-CoV-2 IgG), 74.4%, 56.1% (Acro 2019-nCoV IgG), 69.5%, 46.3% (Acro 2019-nCoV IgM), 97.5%, 71.9% (Xiamen Biotime SARS-CoV-2 IgG), and 88.8%, 81.3% (Xiamen Biotime SARS-CoV-2 IgM)
Sample Size
62 patients & 53 controls
Peer-reviewed
no
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements